Trials / Terminated
TerminatedNCT00827489
Study Evaluating HTC-867 in Healthy Young and Elderly Subjects
Ascending Single Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HTC-867 Administered Orally to Healthy Subjects
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 72 (estimated)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to assess the safety and tolerability of ascending single oral doses of HTC-867 in healthy young and elderly subjects. This study will also evaluate the way the drug enters and leaves the blood and tissues over time and how the drug acts on and in the body in a fasted and fed state.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HTC-867 | |
| OTHER | Placebo |
Timeline
- Start date
- 2009-01-01
- Primary completion
- 2009-04-01
- Completion
- 2009-04-01
- First posted
- 2009-01-22
- Last updated
- 2009-09-02
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00827489. Inclusion in this directory is not an endorsement.